» Articles » PMID: 38463018

Management of CRSwNP in Latin America: A Multidisciplinary Consensus from an Expert Working Group

Overview
Date 2024 Mar 11
PMID 38463018
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory condition of the nasal and paranasal tissues, characterized by the presence of bilateral nasal polyps. While etiology and pathogenetic mechanisms are heterogeneous and complex, in most patients, disease is mediated predominantly through type 2 inflammatory processes. Clinical management is challenging, and a multidisciplinary approach is preferred. Principal treatment approaches are the use of local/systemic corticosteroids and sinonasal surgery, although outcomes can be unsatisfactory. Recent availability of biological therapies targeting underlying inflammatory processes can offer effective treatment options in uncontrolled disease. Specialist guidelines greatly assist clinical decision-making, although as these are chiefly written from a global/international perspective, they may not wholly accommodate disease patterns and clinical practice at a regional level. An expert panel of specialists from Latin America was convened to develop regional guidance on the management of CRSwNP through a consensus approach. The present article presents the chief observations and recommendations which can provide guidance for clinicians in the Latin American region.

References
1.
Han J, Bosso J, Cho S, Franzese C, Lam K, Lane A . Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2021; 11(10):1407-1416. DOI: 10.1002/alr.22851. View

2.
Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T . Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2011; 67(1):91-8. DOI: 10.1111/j.1398-9995.2011.02709.x. View

3.
Fokkens W, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J . EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019; 74(12):2312-2319. PMC: 6972984. DOI: 10.1111/all.13875. View

4.
Bachert C, Han J, Wagenmann M, Hosemann W, Lee S, Backer V . EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2020; 147(1):29-36. DOI: 10.1016/j.jaci.2020.11.013. View

5.
Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W . Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2012; 131(1):110-6.e1. DOI: 10.1016/j.jaci.2012.07.047. View